Quick Answer
XBiotech Inc. reported Research And Development Expense of $47.39 million for the year ending 2025.
- XBiotech Inc. showed an increase of +25.5% in Research And Development Expense from 2024 to 2025.
- This data is from XBiotech Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: $3.25 million | Q3 2014: $4.34 million | Q1 2015: $6.78 million | Q2 2015: $4.38 million | Q3 2015: $9.73 million | Q1 2016: $7.81 million | Q2 2016: $11.22 million | Q3 2016: $9.77 million | Q1 2017: $8.19 million | Q2 2017: $7.40 million | Q3 2017: $4.93 million | Q1 2018: $2.99 million | Q2 2018: $3.95 million | Q3 2018: $3.94 million | Q1 2019: $4.53 million | Q2 2019: $4.69 million | Q3 2019: $4.53 million | Q1 2020: $1.16 million | Q2 2020: $2.57 million | Q3 2020: $2.35 million | Q1 2021: $4.63 million | Q2 2021: $9.25 million | Q3 2021: $5.60 million | Q1 2022: $6.82 million | Q2 2022: $10.39 million | Q3 2022: $7.01 million | Q1 2023: $6.23 million | Q2 2023: $11.27 million | Q3 2023: $7.55 million | Q1 2024: $9.83 million | Q2 2024: $12.98 million | Q3 2024: $7.13 million | Q1 2025: $11.62 million | Q2 2025: $5.34 million | Q3 2025: $5.08 million.
- Over the full 13 years of available data (2013 to 2025), XBiotech Inc.'s Research And Development Expense has grown by 497.2%.
- Historical annual values: Fiscal year 2025: $47.39 million | Fiscal year 2024: $37.76 million | Fiscal year 2023: $32.85 million | Fiscal year 2022: $31.54 million | Fiscal year 2021: $28.27 million | Fiscal year 2020: $9.53 million | Fiscal year 2019: $24.09 million | Fiscal year 2018: $15.73 million | Fiscal year 2017: $26.42 million | Fiscal year 2016: $42.49 million | Fiscal year 2015: $31.31 million | Fiscal year 2014: $14.33 million | Fiscal year 2013: $7.94 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: